NCT04798313View on ClinicalTrials.gov

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

December 7, 2020

Study Completion Date

December 31, 2020

Conditions
Osteoporosis, Postmenopausal
Interventions
DRUG

MW031

Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.

DRUG

Prolia®

Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.

Trial Locations (1)

255400

PKUCare Luzhong Hospital, Zibo

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY

NCT04798313 - Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults | Biotech Hunter | Biotech Hunter